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2.  ABBREVIATIONS 
 
 
AGA  antigliadin antibody 
CD  coeliac disease 
CD3+  CD3 positive lymphocytes 
CD4+  helper T lymphocytes 
CD8+  suppressor T lymphocytes 
DH  dermatitis herpetiformis 
DMFT  decayed, missing, filled teeth 
ELISA  enzyme-linked immunosorbent assay 
EmA  endomysium antibody 
GFD  gluten-free diet 
α/β TcR+  α/β T cell receptor positive lymphocytes        
γ/δ TcR+  γ/δ T cell receptor positive lymphocytes 
IgA  immunoglobulin A 
IgG  immunoglobulin G 
IgM  immunoglobulin M 
KI  potassium iodine 
PMI  panoramic mandibular index 
RAU  recurrent aphthous ulcer              
TGA  transglutaminase antibody 
TG2  tissue type transglutaminase 
SS  Sjögren’s syndrome 
TcR  T cell receptor 
 
  
 
9 
3.  ABSTRACT 
  
 
Patinen P. Oral findings in coeliac disease and dermatitis herpetiformis. 
Institute of Dentistry and Institute of  Clinical Medicine, University of Helsinki, 
Hospital for Skin and Allergic Diseases, Hospital for Children and Adolescents, Huslab / Oral 
Pathology Unit, and Department of Oral and Maxillofacial Surgery, Helsinki University 
Central Hospital and Departments of Otorhinolaryngology and Maxillofacial Surgery, Internal 
Medicine and Dermatology, Tampere University Hospital, Tampere, Finland 
 
 
Coeliac disease (CD) is an autoimmune disorder with small-intestinal mucosal inflammation 
caused by wheat gluten and related cereal peptides in genetically predisposed individuals. 
Dermatitis herpetiformis (DH) is a blistering skin disease in which the patients have mostly 
subclinical gluten sensitive enteropathy, i.e. CD, and pathognomonic IgA deposits in the skin 
and oral mucosa. Sjögren’s syndrome (SS), which occurs in about 3% of the patients with CD 
and DH, also has an autoimmune background and is characterized by an inflammation of the 
salivary glands resulting in dryness of mouth.  
 
In the first study (I) the occurrence of IgA antigliadin antibodies (AGA) in the saliva and 
serum of ten untreated and ten gluten-free diet (GFD) treated patients with DH was examined 
by a solid-phase enzyme immunometric assay (Gluten IgA EIA; Pharmacia, Uppsala, 
Sweden). The salivary IgA AGA levels, however, were only about 10% of the corresponding 
levels in the serum and similar to those of healthy controls. In addition, salivary IgA AGA 
levels did not decrease during GFD treatment unlike the serum IgA AGA levels. Therefore, it 
was concluded that salivary IgA AGA cannot be used for screening the enteropathy of the 
patients with DH or monitoring the GFD treatment. In the second study (II), 
immunohistochemical stainings detected only very low numbers of intraepithelial γ/δ T cell 
receptor (TcR) bearing lymphocytes in the buccal mucosa of 13 untreated and 13 GFD treated 
patients with DH. This was in sharp contrast to the jejunal epithelium, where the numbers of 
γ/δ TcR+ lymphocytes were high in line with their indicator role for gluten-sensitive 
enteropathy.  
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In the third study (III) wheat gliadin, but not potassium iodine, challenged buccal epithelium 
showed an influx of CD4+ lymphocytes (p=0.06) at 12 h in all five patients with DH but no 
marked changes in the numbers of CD8+ cells. The numbers of α/β TcR+ lymphocytes were 
increased (p=0.03) in the lamina propria but the numbers of  γ/δ TcR+ cells remained at a 
very low level both in the epithelium and lamina propria.. It was concluded that the oral 
mucosa in DH are capable of reacting to locally applied gliadin by CD4+ and α/β TcR+ 
lymphocyte response. However, the oral mucosa were resistant to producing any macroscopic 
or microscopic DH lesions when challenged by potassium iodine which is in sharp contrast to 
what happens in the skin.   
 
Patients with CD are known to have an increased frequency of recurrent aphthous ulcers and 
coeliac-type dental enamel defects whereas patients with SS suffer from dryness of mouth and 
have an increased risk for dental caries. The fourth study (IV) examined whether patients 
suffering concomitantly from CD and SS have an even higher frequency of oral mucosal, 
dental and salivary abnormalities than patients with either disorder alone. Twenty patients 
with CD+SS and 20 age and sex matched controls with CD and 20 with SS were studied. Oral 
mucosal changes were most common in SS (80%) followed by CD+SS (65%) and CD (40%). 
Coeliac-type dental enamel defects were found in 89% in CD+SS and in 88% in CD 
compared to only 25% in SS (p<0.001). The median number of teeth was 6 in the CD+SS, 24 
in the CD and 22 in the SS group. The DMF index was higher (p<0.005) in the CD+SS than 
in the CD group. Interestingly, the CD+SS group was characterized by a higher salivary flow 
rate (p<0.001) and lower inflammarory focus score in the salivary glands (p<0.01) than the SS 
group. These differences suggest that GFD treatment may alleviate autoimmune inflammation 
in SS when the patient has concomitant CD. Overall, the co-occurrence of CD and SS should 
be recognized due to its effects on dental and oral mucosal health.  
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4.  INTRODUCTION 
 
 
Coeliac disease (CD) is an autoimmune disorder with small intestinal mucosal inflammation 
caused by wheat gluten and related cereal peptides in genetically predisposed individuals 
(Trier 1991, Mäki&Collin 1997). In the past few years, knowledge about the pathogenesis of 
CD has increased greatly. Gliadin triggers a cascade of reactions in which activated T cells 
induce an inflammatory process in the jejunal mucosa with subsequent formation of 
autoantibodies to transglutaminase enzyme (Dieterich et al 1997). The end point of these 
events is jejunal mucosal damage, i.e. atrophy of the villi, leading to various gastro-intestinal 
symptoms and signs of malabsorption (Sollid et al 1989). Gluten-sensitive enteropathy is 
frequently also subclinical and recent serological screening studies have shown that the 
prevalence of CD may be as high as 1/100 (Mäki et al 2003). Dermatitis herpetiformis (DH) 
is a cutaneous phenotype of CD showing pathognomonic IgA deposits in the skin and oral 
mucosa (Reunala 2001). The blistering rash and the mostly subclinical enteropathy respond 
well to treatment by a gluten-free diet (GFD) (Garioch 1994). 
 
In the early 1980s tests for the measurement of antigliadin antibodies (AGA) in the serum 
were developed (Unsworth et al 1981, Vainio et al 1983). The results showed that screening 
of IgA class AGA was useful in search for gluten-sensitive enteropathy in CD and DH 
(Vainio et al 1985). At the same time an increased number of intraepithelial γ/δ TcR+ 
lymphocytes in the jejunal mucosa was found to be a constant marker for gluten-sensitive 
enteropathy in CD and DH (Halstensen et al 1989, Savilahti et al 1992). The first aim of the 
present study in patients with DH was to examine whether IgA AGA are secreted into the 
saliva and these salivary antibodies could then be used as a marker for gluten-sensitive 
enteropathy. A further aim was to investigate whether γ/δ TcR+ lymphocytes occur in the oral 
mucosa in similar high numbers as in the jejunal mucosa and whether application of gliadin or 
potassium iodine causes increased influx of these cells into the mucosa. 
 
Patients with CD and DH are known to have recurrent aphtous ulcers (RAU) and coeliac-type 
dental enamel defects, both of which might be the only presenting symptoms in CD 
(Fergusson et al 1976, Aine 1996). Earlier reports have described also glossitis and cheilitis as 
typical findings associated with CD (Cooke et al 1953, Barry et al 1974). CD and DH are 
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associated with Sjögren’s syndrome (Collin et al 1994, Iltanen et al 1999), an autoimmune 
disorder not linked with gluten sensitivity but characterized by inflammation of the salivary 
glands. Dryness of the mouth and increased risk for caries are consequences of the decreased 
salivary secretion in SS (Konttinen et al 1997). CD patients with associated SS could have an 
even higher risk for oral mucosal and dental lesions. Therefore, one aim of the present study 
was to examine whether patients suffering concomitantly from CD and SS have higher 
frequencies of oral mucosal, dental and salivary abnormalities than patients with either 
disorder alone.  
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5.  REVIEW OF LITERATURE 
 
5.1  Coeliac disease and dermatitis herpetiformis 
 
5.1.1 Coeliac disease 
 
CD is an autoimmune disorder characterized by inflammation, villous atrophy and crypt 
hyperplasia of the small-intestinal mucosa (Mäki&Collin 1997).  The mucosal lesion develops 
in genetically susceptible individuals after ingestion of dietary gluten and heals when gluten-
containing cereals are withdrawn from the diet (Trier 1991). The prevalence in Western 
countries may be as high as 1/100 (Fasano et al 2003, Mäki et al 2003). CD can appear at any 
age and in adults it is more common in women than in men (Mäki&Collin 1997). Patients 
may present with typical minor symptoms, such as loose stools and abdominal discomfort, or 
with apparent symptoms, such as steatorrhoea or malabsorption, leading to iron and folic acid 
deficiency and hypocalcaemia. About 20% of the patients do not have apparent 
gastrointestinal symptoms and therefore present with a so-called silent or subclinical form of 
the disease (Collin et al 1997). Due to this CD easily remains underdiagnosed if no 
serological screening tests are performed (Corazza et al 1993, Mäki et al 2003). Current 
diagnostic criteria for CD comprise the finding of a typical mucosal lesion of subtotal or 
partial villous atrophy, after which induction of a GFD should result in histological recovery 
and disappearance of gastrointestinal symptoms (Trier 1991, Mäki&Collin 1997).  
 
 
5.1.2 Dermatitis herpetiformis 
 
Dermatitis herpetiformis (DH) is a life-long blistering skin disease with predilection sites on 
elbows, knees and buttocks.  All patients have pathognomonic granular IgA deposits in the 
skin (van der Meer 1969) and also in the oral mucosa (Hietanen&Reunala 1984).  A very 
close relation exits between DH and CD, all patients with DH have at least subclinical or 
latent CD in the small intestine, and the rash also responds to a GFD. Patients with DH may 
also present gastrointestinal symptoms typical of CD. Several findings indicate that DH is a 
cutaneous phenotype of CD (Hervonen et al 2000, Reunala 2001, Fry 2002). 
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The prevalence rate of DH in Finland has been reported 1:1500, which is a quarter of that of 
coeliac disease  (Collin et al 1997). Men slightly predominate among Finnish patients with 
DH, unlike in CD (Collin 1996, Mäki&Collin 1997). The common age at the onset of DH is 
30-40 years, but it can appear at any age (Reunala 2001).  
 
The formation of clinically visible blisters in DH starts with the formation of neutrophil 
micro-abscesses at the summits of dermal papillae. These are quickly transformed by oedema 
into micro-vesicles which then coalescence to form a unilocular subepidermal bulla. The 
whole process takes about 24 hours. The split occurs in lamina lucida (Klein et al 1983). DH 
blister fluid contains increased collagenase-, gelatinase-, and elastase-like enzymatic activity 
(Oikarinen et al 1986). Oral KI aggravates DH, and KI applied to the uninvolved skin will 
produce clinical lesions similar to those of DH (Haffenden et al 1980). By using a KI 
application method, Airola et al (1997) showed that the initial event in blister formation is 
early actication of urokinase plasminogen activator with subsequent activation of various 
metalloproteases and disruption of the basement membrane. The actication of some of these 
enzymes occurred already before any influx of lymphocytes or polymorphonuclear leucocytes 
was seen in the dermis (Airola et al 1997). 
 
 
5.1.3  Jejunal findings 
 
In untreated CD the characteristic abnormalities in the small-intestinal mucosae are villous 
atrophy, crypt hyperplasia and an increased density of inflammatory cells in the epithelium 
and lamina propria (Trier 1991). The mucosal lesion heals with a gluten-free diet and 
deteriorates further if the patient resumes a gluten-containing diet (Mäki&Collin 1997). 
 
Increased density of lymphocytes bearing the γ/δ T cell receptor (TcR) is present in the 
jejunal mucosa, and this seems to be a constant marker for untreated CD and DH (Halstensen 
et al 1989, Holm et al 1992, Savilahti et al 1992).  In GFD treated CD patients a decrease 
occurs in the density of the γ/δ T cells, but the level, however, remains elevated although the 
mucosae are macroscopically recovered (Iltanen et al 1999, Järvinen et al 2003). The density 
of jejunal α/β TcR+ lymphocytes is also increased in untreated patients with CD, but their 
numbers decrease to normal levels after the initiation of a GFD (Järvinen 2003).  
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Lymphocytes bearing γ/δ TcR are found, particularly in the jejunal epithelium, whereas α/β 
TcR+ lymphocytes are found both in the jejunal epithelium and the lamina propria. 
 
The term latent CD is applied to patients who have been shown to have a normal villous 
architecture on a normal gluten-containing diet, but show increased intraepithelial γ/δ T cell 
counts and/or IgA EmA or TGA levels in the serum, and who later on develop villous 
atrophy. Patients with subclinical CD present no symptoms. Increased γ/δ T cell counts 
together with intestinal fluid IgA AGA also seem to be markers for latent CD (Holm et al 
1992). 
 
It has been suggested that γ/δ TcR+ lymphocytes may have a special function in protecting 
mucosal surfaces by eliminating infected or otherwise damaged epithelial cells (Janeway et al 
1988). These cells have the ability to recognize non-peptidic molecules commonly associated 
with micro-organisms and stressed cells (Boismenu&Havran 1997). The γ/δ TcR+ 
lymphocytes may also play a role in various inflammatory and autoimmune conditions. These 
cells can secrete lymphokines and express cytolytic activity in response to antigenic 
stimulation. A consistent feature of the γ/δ TcR+ lymphocytes is a rapid and transient release 
of bioactive polypeptides such as interferon-gamma (Ferrick et al 1995). In the normal human 
oral epithelia the γ/δ TcR+ lymphocytes are rare (Pepin et al 1993). 
 
 
5.1.4 Serological findings 
 
Antigliadin antibodies 
 
The jejunal mucosa of patients with untreated CD is always heavily infiltrated with plasma 
cells containing and producing IgA (Rubin et al 1965), most of which seem to be IgA AGA 
(Falchuk&Strober 1974). The number of IgA-containing cells falls rapidly when a GFD is 
started and becomes normal within a few months both in CD and DH (Reunala 1978). At the 
same time IgA AGA levels decrease in the serum and then rise again when a gluten challenge 
is performed (Vainio et al 1985). Methods of measuring IgA AGA include 
immunofluorescence (Unsworth et al 1981), enzyme-linked immunosorbent assay (ELISA) 
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(Vainio et al 1983), diffusion-in-gel ELISA (Kilander et al 1983) and solid-phase 
radioimmunoassay (Ciclitira et al 1985).  
 
The median sensitivity of IgA AGA in screening of CD is 87% and the specificity somewhat 
lower, 83% (Table 1). AGA and especially IgG AGA are also found in other gastrointestinal 
diseases and in disorders such as rheumatoid arthritis and atopic dermatitis (Collin et al 2002). 
They may also occur in healthy individuals not carrying the risk of HLA DQA/DQB alleles 
for CD (Mäki&Collin 1997). IgG-class AGA detects CD when the patient has selective IgA 
deficiency, the frequency of which is 2-3% in CD (Savilahti et al 1971, Kokkonen et al 1982, 
Korponay-Szabo et al 2003). 
  
IgA AGA measured by in-house ELISA had a high negative predictive value (99%) in one 
study and it was suggested as a suitable first-line test to exclude CD (Bowron et al 2000). 
When IgA AGA is positive, a suitable confirming test is a some more specific test, i.e. 
measurement of IgA EmA or TGA. This step-wise approach to screening for CD was shown 
to yield cost savings in one recent study (Bowron et al 2000).  
 
 
Table 1. Sensitivities and specificities of various serological tests in the screening of coeliac 
disease. 
 
IgA antibody test Sensitivity % Specificity % 
 Median Range Median Range 
Antigliadin antibody  
ELISA/EIA 
87 31-100 83 82-100 
Endomysial antibody  
Indirect immunofluorescence 
93 85-100 100 95-100 
Transglutaminase antibody  
ELISA 
95 92-98 95 94-99 
Data from seven studies (Collin et al 2002) 
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Endomysium and transglutaminase antibodies 
 
IgG-class reticulin antibodies were first described in sera of patients with CD using an 
indirect immunofluorescence method. Thereafter, IgA-class reticulin antibodies were shown 
to be more specific in the screening of CD (Hällström 1989). Due to a rather low sensitivity, 
the IgA-class reticulin antibody measurements are now considered to be of limited value in 
the diagnosis of CD (Collin et al 1994). 
 
The IgA-class endomysial antibody test (EmA) was introduced by Chorzelski et al (1984). 
This indirect immunofluorescene test using monkey oesophagus and then human umbilical 
cord as substrate was shown to be more sensitive and specific than the previous reticulin 
antibody test in the screening and diagnosis of CD (Table 1). Recently, it was shown that the 
endomysial antigen binding IgA antibodies from the serum of patients with CD was tissue 
type transglutaminase which occurred also in human tissues (Dieterich et al 1997, Schuppan 
2000). Thereafter, an ELISA test was developed to measure these antibodies in the sera of 
patients with CD and DH (Dieterich et al 1998, Sulkanen et al 1998, Dieterich et al 1999). 
The IgA TGA ELISA test using recombinant tissue transglutaminase is both sensitive and 
specific and is now widely used in the screening and diagnosis of CD (Johnston et al 2003, 
Table 1). In addition, the efficacy of GFD treatment can be monitored by measuring IgA TGA 
(Dieterich et al 1998, Sulkanen et al 1998, Dieterich et al 1999). The antibody levels decrease 
when the jejunal mucosa heals on a GFD, and continuously positive results often indicate 
faults on the dietary treatment. 
 
 
5.1.5  Treatment 
 
Gluten-free diet in coeliac disease 
 
The treatment of CD is a life-long GFD (Trier 1991, Mäki&Collin 1997). Wheat gluten can 
be divided into alcohol-soluble fractions, prolamins, and non-soluble fractions. Prolamins in 
wheat are called gliadins, which can be further divided into alpha, beta, gamma and omega 
fractions according to electrophoretic mobility. Prolamins in rye are called secalins, in barley 
hordeins and in oats avenins. Oats, however, has been reported to be tolerated by patients with 
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CD without any harm to the small intestine and is now generally considered safe for these 
patients. It seems that only 60-80% of patients with CD maintain a strict GFD (Collin et al 
1996). Occasional intake of gluten may not necessarily produce gastrointestinal symptoms, 
but continuously eating small amounts of gluten seems to be a reason for mucosal 
inflammation with increased numbers of intraepithelial lymphocytes and increased levels of 
IgA AGA, EmA and TGA  (Mayer et al 1991, Collin et al 1996).  
 
 
Gluten-free diet and dapsone in dermatitis herpetiformis 
  
The rash in patients with DH can be controlled by Dapsone and a GFD (Fry et al 1973, 
Reunala et al 1977, Garioch et al 1994). It takes several weeks or months for the rash to 
respond to the diet (Garioch) and therefore the initial treatment suitable for most patients is to 
start with a combination of dapsone and GFD. Dapsone produces rapid relief of itching, and 
the rash subsides within a few days. In contrast to GFD, it has no effect on the enteropathy, 
nor on the cutanous IgA deposits. Most patients with DH require 50 to 100mg of dapsone 
daily to control the rash (Fry et al 1973, Reunala et al 1977, Garioch et al 1994). The majority 
of patients tolerate dapsone well, but there are risks for dose-related haemotological side-
effects. Dapsone 100mg daily or higher doses may cause hemolysis leading to a fall in 
haemoglobin and most patients have a small degree of methaemoglobinaemia (Leonard&Fry 
1992). Sensory or motor neuropathies may appear after high-dose, long-term dapsone 
treatment, and the most severe side-effect, although very rare, is agranulocytosis, which 
usually appears within the first few months of treatment (Reunala 2001). 
 
GFD is the treatment of choice for all patients with DH because both the rash and enteropathy 
improve (Fry et al 1973, Reunala et al 1977, Garioch et al 1994). The rash responds to GFD 
regardless of whether the patient has flat or normal appearing jejunal mucosa (Reunala 1978). 
In a few patients with DH the rash is very sensitive to minor amounts of eaten gluten, and 
flare-up the rash is seen especially at the onset of GFD treatment. About 90% of the Finnish 
patients with DH adhere well to a GFD and half of them can stop using dapsone within 2-3 
years (Reunala et al 1977, Collin et al 1996). Similarly, in British patients it takes a mean of 2 
years for cessation of dapsone therapy (Gawrodger et al 1984). The rash in patients with DH 
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is not activated by eating oats, and this cereal is now considered safe for the patiens (Hardman 
et al 1997, Reunala 2001).  
 
 
 
5.1.6  Pathomechanisms 
 
Autoimmunity in coeliac disease 
 
It is widely accepted that the mucosal damage in CD is caused by an immunological 
mechanism. Both mucosal cellular (Trier 1991) and humoral (Sollid et al 1997) immune 
systems are activated, and the gliadin fraction of ingested gluten seem to be the trigger. Serum 
IgA antibodies recognize enzyme tissue transglutaminase (TGA2), which can be found in 
activated endothelial, fibroblast and mononuclear cells (Dieterich et al 1997). Tissue 
transglutaminase has an important role in cell homeostasis and regulates cell proliferation, 
differentiation and apoptosis (Shan et al 2002). Gliadin acts as a substrate for tissue 
transglutaminase (Dieterich 1999, Ciccocioppo et al 2003). Gliadin-specific HLA DQ2 and 
DQ8 restricted T cells can be found in the small-intestinal mucosal lesions (Lundin et al 
1993). Antigen-presenting cells in the lamina propria present gluten peptides to CD4+ T cells 
via their HLA DQ molecules. Tissue transglutaminase modifies gliadin peptides through 
deamidation of glutamine residues to negatively charged glutamic acid, which facilitates the 
binding of gliadin peptides to the peptic groove of HLA DQ2 and DQ8 molecules resulting in 
increased T cell reactivity (Molberg et al 1998). Activated T cells induce a local inflammatory 
response that may continue as long as gliadin is present. Stimulated T cells secrete Th 1 
cytokines such as TNFα and γ- interferon, which can further damage the small-bowel mucosa 
and lead to enteropathy (Sollid et al 1997, Nielsen et al 1998). TNFα triggers intestinal 
fibroblasts to secrete matrix metalloproteinases (MMPs), leading to mucosal destruction by 
dissolution of connective tissue. IL-15 increases the number of intraepithelial γ/δ TcR+ and 
CD 94+ cells only in coeliacs. Th 2 response at the intestinal level results in the formation of 
autoantibodies (Picarelli et al 1996), which may also have a direct role in the pathogenesis of 
small-intestinal mucosal damage. 
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The coexistence of autoimmune diseases and CD might be the result of molecular mimicry, 
by which gliadin or TG2 activates T cells that are cross-reactive with various self antigens in 
genetically susceptible hosts, and lead to chronic organ-specific autoimmune disease via 
epitope spreading. Tissue transglutaminase might also generate neoantigens by cross-linking 
or deamidation of other external or self-antigens (Schuppan 2000). 
 
    
IgA in the skin in dermatitis herpetiformis  
 
Granular IgA deposits in dermal papillae are characteristic for DH (van der Meer 1969). They 
are deposited throughout the skin, but greater amounts seem to be present together with 
complement (C3) near the active lesions (Zone et al 1996). IgA deposits have been localized 
in close association with microfibrillar bundles of elastic fibres in the papillary dermis and in 
the dermoepithelial junction below the basal lamina. The exact site of interaction between IgA 
and specified structure in DH skin is unknown. No circulating IgA autoantibodies against any 
dermal components in the sera of patients with DH have been found, which is in sharp 
contrast to findings in linear IgA disease. Recently Sardy et al (2002) showed that IgA 
deposits colocalize with epidermal transglutaminase (TG3) in patients with DH and suggested 
that this might be the autoantigen in DH skin. 
 
Efforts to isolate functional IgA from DH skin have failed. IgA1 is the dominant subclass and 
either minimal or no deposits of IgA2 are found (Hall&Lawley 1985). The findings suggest 
that the IgA in DH skin may not arise from a gastrointestinal source as previously thought. 
After several months on GFD treatment IgA and C3 deposits decrease and may disappear, and 
IgA has been shown to return with the start of gluten-containing diet (Reunala 1978, Leonard 
et al 1983). This has led to a hypothesis that circulating immune complexes originating from 
the gut and composed of IgA antibodies attached to antigen, possibly gluten, could be 
deposited into DH skin. Circulating IgA immune complexes can be detected in the sera of 
patients with DH, and increased levels have been found after wheat ingestion. IgA immune 
complexes, however, occur also in the sera of patients with coeliac disease who have neither 
skin disease nor cutaneous IgA deposits. It has been suggested, that excess IgA tissue 
transglutaminase antibodies could be deposited into the skin due to cross-reactivity with 
cutaneous transglutaminases. Tissue transglutaminase is also involved in the intermolecular 
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closs-linking of type VII collagen that occurs near the areas where IgA depostis in DH skin 
are found (Raghunath et al 1996, Sardy et al 2002). Whether there is a specific dermal 
autoantigen in DH skin related to tissue transglutaminase is not yet known. 
 
 
5.1.7 Genetic background  
 
The occurrence of CD and DH in first-degree relatives ranges between 5% and 15% (Holm et 
al 1992). The coexistence of CD in monozygotic twins has been reported to be 80% (Polanco 
et al 1991, Hervonen et al 2000). Approximately 95% of patients with CD and DH share the 
HLA DR3- DQ2 haplotype, coded by the DQA1*0501 and DQB1*0201 alleles in the short 
arm of chromosome six (Sollid et al 1989, Polvi et al 1996). Most of the remainder express 
the DR4-DQ8 haplotype encoded by DQA1*0301, DQB1*0302 alleles (Polvi et al 1996).  
 
The prevalence of HLA DQ2 is 20-30% in the normal population (Sollid et al 1989, Polvi et 
al 1996) and, therefore, only a minority of people with this HLA phenotype will develope CD. 
This suggests that additional, probably non-HLA-linked genes are involved in the 
pathogenesis of CD.  Genome-wide screening studies have resulted in a number of proposals 
for candidate non-HLA gene regions.  So far, no gene or gene region has been found outside 
HLA DQ, and any such additional genes are likely to have a moderate or minor effect on the 
pathogenesis of CD (Liu et al 2002). 
 
 
 5.1.8   Associated diseases 
 
A close association exists between coeliac disease and Sjögren’s syndrome. In a Finnish 
study, 3.3% of the patients with CD had associated Sjögren’s syndrome, whereas the 
frequency was 0.3% in the disease controls (Collin et al 1994). On the other hand, 14.7% of 
the patients with SS were found to have CD in a recent Finnish study (Iltanen et al 1999). 
Testing serum anti TGA has been shown to be a reliable screening method to find coexisting 
CD in patients with SS (Luft et al 2003).  
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CD occurs in 2-5% of patients with type I diabetes or autoimmune thyroid disease and vice 
versa (Collin et al 2002, Hervonen et al 2004). Patients with multiple endocrine disorders and 
Addison’s disease may also have concomitant CD. CD, SS and type I diabetes are associated 
with HLA DR3 and this genentic link is likely to contribute to the concomitant occurrence of 
these autoimmune disorders. GFD may be beneficial in the treatment of the associated 
endocrinological diseases in CD (Collin et al 2002). 
 
Patients with CD and DH are known to be at risk of contracting lymphoma (Collin et al 
1996). The most established lymphoma associated with CD is enteropathy-type intestinal T 
cell lymphoma. This rare lymphoma is often complicated by perforation of the small intestine, 
and the outcome is poor. B-cell lymphoma may also occur in CD. The precise frequency of 
malignancy in CD is unknown, but it has been estimated that for all lymphoma the prevalence 
is 0-7% in patients with untreated CD. GFD treatment has been shown to protect against 
lymphoma both in CD and DH (Holmes et al 1989). 
 
Bone mass density has been shown to be significantly lower in patients with untreated CD 
compared to CD patients treated with GFD or controls (Corazza et al 1995). Osteopenia has 
also been reported in patients with DH (Di Stefano et al 1999). Untreated CD is characterized 
by low serum calcium and increased levels of 1,25 -vitamin D and secondary 
hyperparathyroidism which causes increased bone turnover (Corazza et al 1995,Valdimarsson 
et al 2000). Untreated patients with CD seem to be at higher risk for bone fractures than other 
people (Vasquez et al 2000). Prospective studies in GFD-treated patients with CD have shown 
that the dietary treatment improves bone mass densitity (Kemppainen et al 1999). 
 
 
 
5.2 Oral findings in coeliac disease and dermatitis herpetiformis 
 
5.2.1 Oral lesions 
 
Recurrent aphthous ulceration (RAU) is one of the most common lesions of the oral mucosa, 
affecting about 20% of the general population at some time (Axell&Hendricsson 1985). Its 
cumulative prevalence varies from 5 to 66% of the population depending on the group studied 
  
 
23 
(Miller&Ship 1977). There are several reports in the medical literature of RAU being a 
common feature in patients with CD. Ferguson et al (1976) published a study dealing with 
jejunal mucosal abnormalities in patients with RAU, and the improvement in the oral lesions 
when treated with a GFD. Of the 33 patients with RAU, 24% were found to have CD. In other 
studies the prevalence of CD in patients with RAU has varied from 0 to 40% (O’Farelly et al 
1991), but most authors consider the prevalence to be 2-5%. Interestingly, RAU without the 
intestinal lesion typical of CD might also respond to a GFD (Walker et al 1980, Wray 1981, 
O’Farelly et al 1991). In earlier reports glossitis has been reported in up to 90% of patients 
with untreated CD (Cooke et al 1953). Cheilitis and angular stomatitis are considered by most 
authors to support a diagnosis of malnutrition and deficiencies of iron, folic acid and/or 
vitamin B12 (Barry et al 1974, Wray et al 1978), all of which are also typical signs of CD. 
The prevalence of cheilitis and angular stomatitis in CD varies in different studies between 4 
and 50% (Wray et al 1978). A proper dietary treatment with a GFD frequently leads to 
remission of the oral lesions (Barry et al 1974, Ferguson et al 1976). 
 
There is a certain discrepancy in opinions as to the prevalence of oral lesions in DH.  Oral 
mucosal involvement is considered rare by most authors (Rusotto&Ship 1971, 
Munston&Hodgson 1973, Economopoulou&Laskaris 1986) and is seen in less than 10% of 
patients with DH. In contrast, Frazer et al (1973) reported oral mucosal lesions in ten of 15 
patients with DH.  The oral lesions seen were of four main types: erythematous, vesicular, 
purpuric and erosive. The patient group was small and therefore the conclusion on the 
prevalence of oral lesions in two thirds of the patients with DH should be interpreted with 
caution. Both keratinized and non-keratinized oral mucosa can be affected in DH. Lesions 
have been detected on the lips, anterior fauces, hard and soft palate, upper alveolar ridge and 
buccal mucosa. Uvula and tonsillae rarely show lesions in DH (Fraser et al 1973, 
Economopoulou&Laskaris 1986).  The precence of lesions in tonque also seems to be 
uncommon (Rusotto&Ship 1971, Munston&Hodgson 1973, Fraser et al 1973). Nowadays 
agreement exists that, if present, oral DH lesions are small vesicles which soon rupture, 
leaving fibrine-covered, superficial erosions resembling aphthae. Hyperkeratotic areas and 
lesions resembling oral lichen planus might also occur.  DH is now distinguished from linear 
IgA disease, which is not linked with gluten-sensitive enteropathy. In this rare disease oral 
mucosal involvement is apparently more common and consists of often large mucosal 
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erosions (Chan et al 1990). In immunofluorescence examination the subepithelial IgA 
deposists are granular in DH, whereas in linear IgA disease they occur along the basement  
membrane zone in linear fashion (Rantala et al 1985).  
 
 
 
5.2.2 Salivary findings 
 
In addition to being important in speaking and swallowing, saliva is part of the defence 
system of the human body.  Oral mucosae are in continuous contact with different micro-
organisms and food.  Mechanical rinsing of the oral mucosa by saliva moves foreign bodies 
towards strongly acidic stomach.  A sufficient amount of saliva is necessary for the protection 
against oral diseases.  Saliva has many antimicrobial properties. These can be classified as 
non-immunological (lysozyme, lactoferrin, histatins and salivary peroxidase systems) or 
immunological which consist e.g immunoglobulins (Tenovuo 1989). 
 
 
Salivary flow rate 
 
The average unstimulated flow rate over a waking period of 16 hours is about 0.3ml/min and 
the total volume will be about 300 ml of saliva. During sleep, the maximum flow will fall to 
less than 0.1 ml/min, thus producing less than 40 ml of saliva in 7 hours. Studies with various 
foods suggest that during eating the average stimulated flow rate is about 4 ml/min, which 
equal to about 200 ml of saliva per day produced during meals. The total daily flow of saliva 
amounts about 500-600 ml, which is much less than the 1500 ml/24 hours quoted in many 
textbooks (Edgar&O’Mullane 1996). Approximately 45% of this is produced by the parotid 
and 45% by submandibular glands, 5% by sublingual glands and another 5% by oral mucosal 
minor salivary glands (Mandel&Wotman 1976). Besides glandular secretions, human “whole 
saliva” or “mixed saliva” consists of gingival crevicular fluid, oral microbes and epithelial 
cells (Tenovuo 1989).  Normal resting saliva and stimulated salivary secretion rates are shown 
in table 2.  Several diseases affecting salivary glands, such as Sjögren’s syndrome, are 
associated with diminished salivary flow rate (Syrjänen 1982, Atkinson 1990)      
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Table 2.  Classification of salivary secretion rate (ml/min) according to the reference intervals 
of Ericsson and Hardwick (1978) for resting and paraffin-stimulated whole saliva 
 
 Very low    Low Normal 
Resting saliva <0.1 0.1 – 0.25 0.25 – 0.35 (mean: 0.30) 
Stimulated saliva <0.7 0.7 – 1 1 – 3 (mean 1.5) 
Edgar&O’Mullane 1996 
 
 
Salivary immunoglobulins 
 
The immunoglobulins in the whole saliva are mostly IgA class, but also immunoglobulins G, 
M, D and E classes also are present in much lower concentrations (Brandtzaeg 1989). The 
most abundant immunoglobulin in saliva is dimeric secretory IgA (sIgA), which is produced 
by local plasma cells in the major and minor salivary glands (Mestecky et al 1986). In the 
blood, IgA exists primarily as monomer, whereas in secretions IgA is composed of a 300 
kDA IgA dimer, a 70 kDA secretory component and a 15 kDA J -chain (Brandtzaeg 1989). 
Immunofluorescence studies (Korsrud&Brandtzaeg 1982, Moro et al 1984) have localized 
IgA containing plasma cells in salivary glands in the connective tissue around intercalated or 
intralobular ducts, as well as around acini. J chain is usually found within IgA secreting 
plasma cells as well (Moro et al 1984). The secretory component has been localized within 
epithelial cells of the intercalated and intralobular ducts (Korsrud&Brandtzaeg 1982, Moro et 
al 1984). Secretory IgA is remarkably stable and therefore well suited to function in protease-
containing external secretions such as whole saliva (Brandtzaeg 1989). 
 
Two IgA subclasses are present in saliva. IgA1 forms the major component, IgA2 a minor 
component though its concentration is higher in saliva than in other secretions 
(Tappuni&Challacombe 1994). Salivary IgA is absent at birth, but is readily detectable in 
infants at the age of one week (Cole et al 1998). The IgG is the only detectable 
immunoglobulin in the saliva of a newborn, but the concentration decreases to non-detectable 
levels after some months and appears again after tooth eruption (Brandtzaeg 1989). Low 
concentrations of IgG can be detected in the stimulated parotid saliva, but most of the IgG 
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detected in whole saliva enters the mouth from the gingival crevicular fluid, and to it from 
serum (Brandtzaeg 1989). Inversely, only 1.6% - 4% of the total salivary IgA is reported to 
leak from serum into saliva (Strober et al 1970, Delacroix et al 1982). 
 
IgA1 subclass antibodies have been found to Streptococcus mutans, S sanguis and S mitior, 
all important pathogens of dental caries, but also to Bacteroides and Capnocytophaga species, 
which are involved in periodontal diseases. Parotid antibodies to Bacteroides fragilis, B 
gingivalis and Eschericia coli are mainly of the IgA2 subclass (Brown&Mestecky 1985).  
 
McClelland et al and Wallington et al (1972) suggested that elevated salivary IgA levels 
observed in CD and DH derive from the influx of IgA secreting B cells from the intestine. Al-
Bayaty et al (1989) and Hakeem et al (1992) found significantly increased salivary IgA AGA 
levels in untreated children and adults with CD. Due to this they suggested that salivary IgA 
AGA measurements could be used as a non-invasive screening test for CD. Kelly et al (1991) 
and O’Mahony et al (1991) also found salivary IgA AGA in their patients with CD, but the 
levels in saliva did not correlate with the serum levels. No studies on salivary IgA AGA in the 
patiens with DH were published.   
 
 
5.2.3 Dental findings              
 
In 1958, Lindemann described enamel defects in children with non-specific diarrhoea, and 
thereafter several case reports of enamel defects in patients with CD were published 
(Smith&Miller 1979, Rasmussen&Espelid 1980, Nikiforuk&Fraser 1981). Andersson-
Wenckert et al (1984) reported severe enamel hypoplasia in children who suffered from CD.  
Aine (1986) presented a new classification for permanent-tooth enamel defects in CD. They 
consisted of four grades: Grade I, defect in colour of enamel; grade II, slight structural defects 
with typical horizontal grooves; grade III, evident structural defects with deep horizontal 
grooves and large vertical pits; and grade IV, severe structural defects where the shape of the 
tooth may be changed. As many as 96% of the children (Aine 1986) and 83% of adults with 
CD were found to have systematically occurring enamel defects (Aine 1996). The frequency 
was 80% in children with DH and 53% in adults with DH (Aine et al 1992, Aine 1996). This 
enamel finding in DH gave further evidence that subclinical CD has an important effect on 
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the pathophysiology of DH, as enamel is formed in early childhood and DH is often 
diagnosed at a later age. Dental enamel defects were shown to correlate with the small- 
intestinal mucosal damage and the presence of HLA-DR3 by Mäki et al (1991). Lower 
frequencies of coeliac-type enamel defects in CD than in Finland have been reported in Spain 
(53%) and Italy (24%) (Aguirre et al 1997, Rea et al 1997). Overall, coeliac-type dental 
enamel defects have led to a diagnosis of CD in otherwise asymptomatic patients (Aine 
1996).   
 
The frequency of dental caries when compared with that of a control group has been reported 
to be lower in the patients with CD (Andersson-Wenckert et al 1984) or equivalent (Fulstow 
1979, McLoughlin et al 1980). 
 
 
 
5.3 Sjögren’s syndrome  
 
5.3.1 Clinical features 
 
Sjögren's syndrome (SS) has been defined as an autoimmune epithelitis characterised by 
lymphocytic infiltration of exocrine glands and epithelia in multiple sites. In addition to the 
involvement of the exocrine glands, it is also characterized by clinically important 
complications, general symptoms and visceral changes. The involvement of lacrimal and 
salivary glands results in the typical features of dry eyes and dry mouth (sialopenia and 
xerostomia), the so-called sicca complex. Diminished tear fluid secretion causes a sandy 
sensation in the eyes, burning, redness, photosensitivity, eye fatigue, itching and disturbances 
of vision. Parotid gland enlargement occurs in half of the SS patients. Important 
complications include caries and oral candidosis. Although keratoconjunctivitis sicca and 
stomatitis sicca are emphasized in the current diagnostic criteria, all other exocrine glands are 
also involved. This leads to rhinitis sicca (crust building and nose bleeding), pharyngitis sicca 
(dysphagia, hoarse voice), dry trachea (respiratory tract infections) and vaginitis sicca 
(dyspareunia). Most of the patients also have systemic extraglandular manifestations. These 
include general symptoms, the most common of which are fatigue, joint and muscle pain and 
Raynaud’s phenomenon. Visceral symptoms often have an autoimmune character and include 
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Hashimoto’s autoimmune thyreoiditis, various forms of interstitial pneumonias, chronic 
atrophic gastritis, primary biliary cirrhosis and autoimmune hepatitis, renal tubular acidosis, 
interstitial cystitis, vasculitic skin changes and neurological manifestations from the 
peripheral and central nervous system.  Polyarthralgia is reported in 84% of the patients and 
synovitis up to 77%, which is why these patients are often taken care of by rheumatologists. 
In addition, these patients have an increased risk of developing a mucosal-associated 
lymphatic tissue (MALT) derived marginal zone lymphoma. Pregnancies in SS-A/Ro and/or 
SS-B/La positive mothers can be complicated by neonatal lupus and/or cardiac conduction 
abnormalities, which are caused by the transplacental passage of the autoantibodies from the 
mother to the child. 
 
SS can be seen alone (primary SS) or in association with other autoimmune rheumatic disease 
(secondary SS) (Moutsopoulos 1994). The diagnostic approach to SS is rather complicated 
because it must include two different goals: firstly, assessment of the ocular and salivary 
components and demonstration of autoimmune features, and secondly, differentiation between 
the primary and secondary variants of the syndrome. Like most of the rheumatic diseases, SS 
lack a single distinguishing feature, however, and the disease is diagnosed based on the 
presence of a combination of clinical and laboratory manifestations.  
 
Different classification criteria sets have been suggested for SS, both before and during the 
First International Symposium on Sjögren's Syndrome held in Copenhagen in 1986, but none 
of these had been validated and universally accepted. In addition to the Copenhagen criteria, 
also Greek, Californian and Japanese criteria were presented. The first validated criteria were 
created and tested in a European Union supported project (Vitali et al 1993). Later these EU 
criteria have been extended to create the American-European consensus criteria (Vitali et al 
2002) which are compiled in Table 3. The American-European Group also reached a 
consensus on a list of exclusion criteria (Table 4). This list is quite similar to the so-called 
Californian criteria and the exclusions in the Californian criteria were also adopted by the 
European Study Group in its preliminary criteria set (Vitali et al 1993). Some modifications 
were made to the earlier list: (a) the category of "anticholinergic" drugs was used instead of 
"antidepressant, antihypertensive, parasympatholytic drugs and neuroleptic agents"; (b) "past 
head and neck radiation treatment" was added as an exclusion criterion; (c) sialoadenosis was 
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deleted. Hepatitis C virus (HCV) infection was added as an exclusion criterion, taking into 
account most of the data emerging from the current literature. 
 
The etiology of SS is unknown, but recent years have brought a clearer understanding of its 
pathogenesis (Pertovaara 2001). In an appropriate genetic background, ie. HLA DR3-DQ2, an 
unknown trigger factor, possibly viral, leads to an immunologically mediated inflammatory 
mechanisms which harms exocrinic glands and their function. Viruses can indeed lead to very 
similar conditions, which is also the reason for the fact that the currently valid American-
European criteria include human immunodeficiency virus (HIV) and HCV among the 
exclusion criteria. T-cell mediated autoimmune responses in the glandular tissue are 
considered of major importance in the pathogenesis of SS (Pertovaara 2001). The role of 
Sjögren specific circulatory anti-SS-A and anti-SS-B antibodies in the inflammatory or 
autoimmune process is not at present solved. The current speculations on the pathogenesis do 
not yet explain the female dominance (90 %), the age of onset (usually 40-50 years) and 
targeting of the exocrine glands.  
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Table 3. American-European Consensus Group classification criteria for Sjögren’s syndrome 
(Vitali et al 2002) 
 
I. Ocular symptoms: a positive response to at least one of the following questions: 
1. Have you had daily, persistent, troublesome dry eyes for more than 3 months? 
2. Do you have a recurrent sensation of sand or gravel in the eyes? 
3. Do you use tear substitutes more than 3 times a day?  
 
II. Oral symptoms: a positive response to at least one of the following questions: 
1. Have you had daily feeling of dry mouth for more than 3 months? 
2. Have you had recurrent or persistently swollen salivary glands as an adult? 
3. Do you frequently drink liquids to aid in swallowing dry food? 
 
III. Ocular signs – that is, objective evidence of ocular involvement defined as positive result for at 
least one of the    following two tests:  
 
1. Schirmer’s I test, performed without anaesthesia (< 5mm in 5 minutes) 
2. Rose bengal score or other ocular dye score (> 4 according to van Bijsterveld’s scoring system) 
 
IV. Histopathology: In minor salivary glands (obtained through normal-appearing mucosa) focal 
lymphocytic sialoadenitis evaluated by an expert histopathologist, with a focus score > 1, defined as 
lymphocytic foci (which are adjacent to normal-appearing mucous acini and contain more than 50 
lymphocytes) per 4mm2 of glandular tissue.  
 
V. Salivary gland involvement: objective evidence of salivary gland involvement defined as 
positive result for at least one of the following diagnostic tests: 
 
1. Unstimulated salivary flow (< 1.5ml in 15 minutes) 
2. Parotid sialography showing the presence of diffuse sialectasias (punctate, cavitary or 
destructive pattern), without evidence of obstruction in the major ducts. 
3. Salivary scintigraphy showing delayed uptake, reduced concentration and/or delayed excretion 
of tracer. 
 
VI. Autoantibodies: presence in the serum of the following antibodies: 
1.    Antibodies to Ro(SSA) or La(SSB) antigens, or both.                                                                     
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Table 4. American-European rules for classification and exclusion criteria of Sjögren’s 
syndrome (Vitali et al 2002) 
 
For primary SS 
In patients without any potentially associated disease, primary SS may be defined as follows: 
1. The presence of any 4 of the 6 items as indicative of primary SS, as long as either item IV 
(Histopathology) or VI (Serology) is positive. 
2. The presence of any 3 of the 4 objective criteria items (that is, items III, IV, V and VI) 
3. The classification tree procedure represents a valid alternative method for classification , 
although it should be more properly used in clinical-epidemiological surveys. 
 
For secondary SS 
In patients with a potentially associated disease (for instance, another well defined connective tissue 
disease), the presence of item I or item II plus any 2 among items III, IV and V may be considered 
as indicative of secondary SS. 
 
Exclusion criteria: 
 
Past head and neck radiation treatment 
Hepatitis C infection 
Acquired immunodeficiency disease (AIDS) 
Pre-existing lymphoma 
Sarcoidosis 
Graft versus host disease 
Use of anticolinergic drugs (since a time shorter than 4 –fold the half life of the drug) 
 
 
 
 
5.3.2 Oral findings 
 
Salivary insufficiency may cause difficulty in chewing, swallowing and phonation, adherence 
of food to buccal surfaces, abnormalities in taste or smell, loss of filiform papillae, fissures on 
tongue, buccal membranes and lips, need for frequent ingestion of liquids and worsening of 
dental caries, but also a chronic Candida infection (Najera et al 1997, Konttinen et al 1997, 
Pertovaara et al 2001). The patients with SS have shown a higher frequency of oral mucosal 
changes, higher decayed, missing and filled surface (DMFS) scores, increased alveolar bone 
loss and higher risk of having adult periodontitis than healthy controls (Najera et al 1997, 
Pedersen et al 1999).  
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6.   AIMS OF THE PRESENT STUDY 
 
 
1. To study the occurrence of antigliadin antibodies in the saliva in patients with DH and 
to examine whether these antibodies could be used for screening of gluten sensitive 
enteropathy. 
2. To examine whether γ/δ T cell receptor bearing lymphocytes occur in the oral mucosa 
in patients with DH in similar high numbers as in the jejunal mucosa. 
3. To investigate the inflammatory reaction caused by potassium iodine and gliadin 
application on the oral mucosa in patients with DH. 
4. To study whether patients suffering concomitantly from CD and SS have a higher 
frequency of oral mucosal, dental and salivary abnormalities than patients with either 
disorder alone. 
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7.  MATERIALS AND METHODS 
 
7.1 Patients and controls  
 
A total of 32 patients with DH (19 untreated, 13 GFD treated)  and 20 CD patients with 
associated SS, together with 20 case controls with CD and 20 with SS, were examined in the 
four different study protocols. 
 
Table 5. Patients with dermatitis herpetiformis and coeliac disease in the present studies 
 (I-IV)  
 
Study design  Patients N 
Sex 
(m/f) 
Mean age 
(range) years 
Controls N  
Sex 
(m/f) 
Mean age 
(range) 
years 
I 
Measurement 
of salivary and 
serum IgA-
AGA 
1. Untreated 
patients with 
DH    
      
2. GFD 
treated  
patients  
with DH 
10 
(7/3) 
 
 
 
10 
(8/2) 
53 
(24-75) 
 
 
 
41 
(23-75) 
Non-disease 
controls 
(hospital 
staff) 
20 
(3/17) 
44 
(29-58) 
II 
Occurrence of 
intraepithelial 
γ/ δ TcR+  
lymphocytes in 
oral mucosa 
1. Untreated 
patients with 
DH 
 
 
2. GFD 
treated 
patients with 
DH 
13 
(9/4) 
 
 
 
13 
(9/4) 
48 
(24-75) 
 
 
 
40 
(23-61) 
Non-disease 
controls 
(hospital 
staff) 
9 
(3/6) 
41 
(25-52) 
III 
Potassium 
iodine and 
gliadin 
challenge of 
oral mucosa 
Dapsone 
treated 
patients with 
DH on a 
normal diet 
6 
(5/1) 
49 
(35-75) 
Non-disease 
controls 
(hospital 
staff) 
2 
1/1 
39 
(37-42) 
IV 
Occurrence of 
oral findings in 
CD patients 
associated with 
Sjögren’s 
syndrome 
Patients with 
CD*+SS 
 
 
 
20 
(1/19) 
 
 
 
61 
(48-78) 
 
 
 
1. Case 
controls with 
CD* 
 
 
2. Case 
controls with 
SS 
20 
(1/19) 
 
 
 
 
20 
(1/19) 
61 
(50-80) 
 
 
 
 
62 
(47-79) 
* three patients with concomitant dermatitis herpetiformis 
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7.1.1 Dermatitis herpetiformis (I-III) 
 
All patients with DH were from a special out-patient clinic in the Hospital for Skin and 
Allergic diseases, Helsinki University Central Hospital.  The diagnosis of DH was based on 
showing IgA deposits in the skin by direct immunofluorescence as previously described 
(Hietanen&Reunala 1984). After the diagnosis the patients received dapsone (25-50mg/day) 
if the rash was active, and stared GFD treatment as previously described (Reunala et al 1977). 
 
Study I.  Salivary and serum IgA AGA were measured in 10 newly diagnosed DH patients at 
the onset of GFD treatment and after the patients had been three months on a GFD. Samples 
were also obtained from 10 patients with DH, who had been on long-term GFD treatment 
(mean 33 months, range 3-156 months).  One of these patients had failed to follow a strict 
GFD and was excluded from the study. Twenty healthy members of hospital staff served as 
controls. 
 
Study II.  Oral mucosal biopsies were taken from 13 consecutive, newly diagnosed patients 
with DH and from 13 patients with DH treated with GFD for a mean of 4.5 years (range 0.5 – 
15 yr). Nine healthy members of hospital staff on a normal gluten-containing diet volunteered 
as controls. Control jejunal specimens with normal villous architecture were obtained from 11 
patients with gastrointestinal symptoms on a normal gluten containing diet. 
 
Study III.  Six patients with DH volunteered for the potassium iodine and gliadin challenge 
study. All patients used dapsone (25-75mg/day) to control the rash. Three newly diagnosed 
patients were on a normal gluten-containing diet, and three had tried GFD, but at the time of 
the study had eaten some gluten every week. Five of the patients had increased IgA AGA and 
four showed IgA EmA (titer 10-1600) in the serum. Small-intestinal biopsy showed subtotal 
or partial villous atrophy in five and inflammatory changes in one patient. Dapsone was 
withdrawn 48 h before the study. Two healthy members of hospital staff served as controls.  
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7.1.2 Coeliac disease and Sjögren’s syndrome (IV)  
 
Study IV. The twenty patients with CD+SS, and the age and sex matched case controls with 
either CD or SS, were from the Department of Internal Medicine, Tampere University 
Hospital. The diagnosis of CD was based on the demonstration of subtotal or partial villous 
atrophy with crypt hyperplasia in small-intestinal mucosal biopsy. SS was diagnosed 
according to the American-European consensus group criteria (Vitali et al 2002). The mean 
duration of CD was 9.3 years and that of SS 8.2 years. Fourteen patients were on a strict GFD 
and six had occasional faults in the diet.  Four patients used prednisone daily (daily dose 
below 10mg) for SS.  
 
 
7. 2.  Clinical investigations (IV)  
 
7.2.1 Oral lesions 
 
Oral mucosal abnormalities were recorded according to the WHO ICD-DA classification 
(WHO 1978) and were grouped topographically (Roed-Pedersen&Renstrup 1969). A 
thorough dental examination was performed and caries status recorded using the DMF index 
(WHO 1997).   
 
 
7.2.2 Dental enamel defects  
 
Coeliac-type dental enamel defects in the incisors were graded by a classification method 
described by Aine (1986). 
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7.3 Collection of saliva and IgA antigliadin antibody assay  
 
7.3.1 Collection of saliva (I, IV) 
 
Whole saliva samples were collected according to a method described by Heintze et al (1983). 
After at least 5 min rest, unstimulated whole saliva was collected for 5 min (study I). Then the 
salivary flow was stimulated by chewing paraffin (2g, melting point 42-44oC, Orion 
Diagnostica, Espoo, Finland), and the stimulated whole saliva was collected for 5 min. 
 
The salivary samples were incubated immediately at 56oC for 30 min in order to inactivate 
proteolytic enzymes and complement.  The samples were then centrifuged for 15 min at 3000 
x g at room temperature.  The supernatants were collected and stored at -40oC.  Serum 
samples were collected simultaneously and they were also stored at -40oC. 
 
 
7.3.2 Antigliadin antibody assay (I) 
 
Serum IgA AGA was assayed using a solid phase enzyme immunometric assay obtained in 
the form of a commercial ELISA kit (Gluten IgA EIA; Pharmacia, Uppsala, Sweden).  IgA 
AGA in the serum (diluted 1/200) is allowed to react with gliadin coated on the surface of a 
microplate well. The absorbance at 420 nm was measured using a microplate photometer and 
the value for each sample was compared with that of a reference serum (pooled patient sera).   
 
Salivary IgA AGA was assayed similarly, except that a 10-fold volume of saliva (diluted 
1/20) was used per assay, as the immunoglobulin concentration in saliva was generally lower 
than in serum. For every patient, the saliva and serum IgA AGA measurements were 
performed in the same ELISA runs. Salivary and serum IgG AGA were measured with a 
gluten IgG EIA assay kit (Pharmacia). 
 
Salivary total IgA was measured using an immunoturbidometric method with an EPOS 5060 
analyzer (Eppendorff, Hamburg, Germany). The anti-IgA antiserum was from DAKO 
(Glostrup, Denmark). 
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7.4 Potassium iodine and gliadin challenge on oral mucosa (III) 
 
Fifty per cent potassium iodine in petrolatum and gliadin powder (30mg; Sigma Chemicals, 
St. Louis, MO, USA) moistened with physiological saline was applied in 8 mm diameter 
aluminium patch test chambers (Finnchamber, Epicon Ltd., Tuusula, Finland).  These were 
fixed with occlusive bandage on buccal mucosa of the molar area just below linea alba.  The 
chambers were removed after 12h and 4 mm punch biopsies were taken from the challenged 
and non-challenged (control) mucosa under 2% lidocaine with epinephrine. 
 
 
7.5 Biopsies and immunohistochemical stainings (II-IV)  
 
7.5.1 Oral and jejunal biopsies 
 
Punch biopsies of 3 mm (II) and 4 mm (III) were taken under 0.5% lidocaine with 
epinephrine from the buccal mucosa of the molar region just below linea alba. A jejunal 
biopsy was taken under gastroscopy (Savilahti 1992). The biopsy specimens were snap-frozen 
in liquid nitrogen, embedded in a mounting media (OCT, Tissue Tek®; Miles, Elkhart, IN, 
USA) and stored at -70oC before use.   
 
 
7.5.2 Immunohistochemical stainings and cell counting  
 
An avidin-biotin peroxidase method was used for staining of the cells as previously described 
by Savilahti (1992). Serial cryostat sections (4-5 µm) were cut, fixed in acetone for 20 min at 
4oC, then in chloroform for 20 min at 20oC and finally washed three times in phosphate-
buffered saline (PBS), pH 7.2.  The buffer was removed, and the sections covered with a 
dilution of monoclonal antibodies in PBS for 1 h.  After washing, endogenous peroxidase was 
blocked by incubation with 0.5% hydrogen peroxidase for 30 min.  A Vectastain Elite ABC 
kit (PK-6102, Vector Laboratories, Burlington, CA, USA) was used for 30 min to show the 
binding of the monoclonal antibodies in accordance with the manufacturer’s instructions.  
Counterstaining was performed with haematoxylin. 
  
 
38 
 
The monoclonal antibodies used were anti-Leu4 (dilution 1:400; Becton Dickinson, Mountain 
View, CA, USA) for CD3+ cells, OKT8 (dilution 1:20; Becton Dickinson) for CD8+ cells, T4 
(dilution 1:20; Coulter Immunology, Hialeah, FL, USA), TcRδ1 (dilution 1:200; T cell 
Sciences, Cambridge, MA, USA) for γ/δ TcR+ cells and βF1 (dilution 1:100, T cell Sciences) 
for α/β TcR+ cells. 
 
Positively stained cells were counted in the epithelium and lamina propria with a light 
microscope through a calibrated graticule at 1000 x magnification.  At least 30 fields (0.09 x 
0.16mm) were counted and the results were given as cells/mm2. In the jejunal epithelium the 
cell numbers were given as cells/mm (Savilahti 1992).  
 
 
7.5.3 Salivary gland biopsies and inflammatory focus score 
 
An incision biopsy was taken from minor salivary glands in the lower lip of 20 patients with 
CD+SS, 20 case controls with CD and 20 case controls with SS (study IV) under local 
anaesthesia (lidocaine with 2% epinephrine).  At least five minor salivary glands were 
harvested.  An inflammatory focus score was calculated by counting from 5µm sections the 
number of mononuclear cell infiltrates containing at least 50 inflammatory cells in a 4mm2 
glandular section under a light microscope using a graticule and 40x magnification 
(Segerberg-Konttinen et al 1986).  
 
 
7.6 Radiological investigations (IV) 
 
A panoramic radiograph was taken from all 60 patients and the state of alveolar bone was 
evaluated by using a panoramic mandibular index (PMI, Benson et al 1991). This was 
obtained by dividing the height of the inferior cortex on the right side of the mandible by the 
distance from the lower border of the mandible to the inferior edge of the mental foramen. 
The alveolar bone resorption index (Packota et al 1988) was calculated for 45 patients with 
teeth by dividing the distance from the inferior border of the mandible to the alveolar crest by 
the distance from the inferior border of the mandible to the lower edge of mental foramen.  
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7.7 Statistical methods  
 
In Study I, the Mann-Whitney U test was used to compare the salivary and serum IgA AGA 
levels in the untreated and GFD treated DH patiets and the control subjects.  Rank correlation 
analysis (Spearman test) was used in calculating the correlations between IgA AGA 
concentrations in serum and saliva.  The Wilcoxon-Pratt paired rank sum test was used for 
comparison of IgA AGA levels before and after GFD treatment. 
 
In Study II, the Mann-Whitney U test was used to compare the numbers of CD3, γ/δ TcR+ 
cells and α/β TcR+ cells in the patients with DH and the control subjects. 
 
In Study III, the permutation test for paired replicates was used to compare the cell counts in 
the challenged and control mucosa.  
 
In Study IV, the results for the patient groups of CD+SS, CD and SS were expressed as means 
and standard deviations, or for skewed parameters as medians and interquartile ranges (IQR). 
Statistical comparison between the groups was made using the Kruskal-Wallis test, Chi-
square, Fisher’s exact test or Fisher-Freeman-Halton test as appropriate.  Post hoc testing of 
several univariate comparisons was made with Hommel adjustments or Dwass-Steel-
Chritchlow-Flinger method at significance level 0.05.  
 
 
7.8 Ethics 
 
The study protocols for the research studies were approved by the Ethical Committees of the 
University Hospital for the Skin and Allergic Diseases, Helsinki (I-III) and the University 
Hospital of Tampere (IV). All patients in the four studies signed confirmation to participate.   
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8.  RESULTS 
 
8.1 Antigliadin antibodies in patients with dermatitis herpetiformis (I)     
 
8.1.1 Salivary and serum IgA and IgG antigliadin antibodies 
 
The median salivary IgA AGA concentration was not significantly different in the ten 
untreated patients with DH compared to the nine patients with DH on a long-term GFD or to 
the 20 control subjects (I, table 2). In contrast to salivary IgA AGA, the untreated patients 
with DH had significantly higher serum IgA AGA levels than the patients with DH on a long-
term GFD (p=0.043) or the healthy controls (p=0.006). No correlation was found between 
salivary and serum IgA AGA levels in the DH patient groups or the control subjects. 
Measurement of IgG AGA in three patients with DH did not disclose these antibodies in the 
saliva although one of the patients had a markedly increased level in the serum (I, table 1). 
 
 
8.1.2 Effect of gluten-free diet treatment on the IgA antigliadin antibodies 
 
The three-month GFD treatment did not alter the median salivary IgA AGA levels in the ten 
patients with DH, and individual changes were small as well (I, table 3). In contrast, the 
median serum IgA-AGA level decreased from 10.5% to 5.5% (p=0.0078).  
 
 
8.2. γ/δ T cell receptor positive lymphocytes in oral and jejunal mucosa in patients with 
dermatitis herpetiformis (II) 
 
The median number of γ/δ TcR+ cells was very low in the buccal epithelium of 13 untreated 
(0.4 cells/mm2; II, table 1) and 13 GFD-treated patients with DH (0.3 cells/mm2). In contrast, 
much higher numbers of α/β TcR+ cells were found, but the densities did not differ between 
the untreated (154 cells/mm2) and GFD-treated (250 cells/mm2) patients with DH. The 
median numbers of CD3 positive lymphocytes were also similar in the two DH patient groups 
and healthy control subjects.  
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In contrast to buccal epithelium, the jejunal specimens (II, table 2) showed significantly 
increased (p<0.001) densities of intraepithelial γ/δ TcR+ cells in the untreated and GFD-
treated patients with DH compared to specimens from the control patients. The median 
numbers of intraepithelial γ/δ TcR+ lymphocytes were somewhat lower than the numbers of 
α/β TcR+ lymphocytes both in the untreated and GFD-treated patients with DH (II, table 2). 
 
 
8.3 Potassium iodine and gliadin challenge on oral mucosa in dermatitis herpetiformis (III) 
 
8.3.1 Clinical and histological findings 
 
Though all six patients with DH had active lesions in the skin at the end of the 12h oral 
mucosal challenge experiment, none of them showed blisters or clinically visible 
inflammatory changes on the potassium-iodine or gliadin-challenge site of the buccal mucosa. 
In agreement with this, none of the biopsy specimens from the challenge sites showed 
subepithelial vesicles or accumulation of polymorphonuclear leukocytes typical of DH 
lesions. 
 
 
8.3.2 T lymphocyte response  
 
In the buccal epithelium all five patients with representative biopsy specimens showed 
increased numbers of CD4+ T lymphocytes (median 114 cells/mm2) in the gliadin challenge 
sites compared to the control sites (50 cells/mm2, p = 0.06, Fig.1). Potassium iodine did not 
cause any marked influx of CD4+ lymphocytes. Similarly, no significant change were found 
in the numbers of CD8+ cells in the gliadin or potassium iodine challenge sites. The α/β 
TcR+ cells did not show any statistically significant change either in the gliadin or potassium 
iodine challenge sites. 
 
In the lamina propria the numbers of CD4+ cells in the gliadin or potassium iodine challenge 
sites did not show any marked increase compared to the control sites. However, the numbers 
of α/β TcR+ cells were increased (p=0.03) in the gliadin challenge site (median 152 cells/ 
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mm
2) compared to the control site (57 cells/ mm2), whereas the potassium iodine challenge 
site did not show any increase. 
 
In contrast to α/β TcR+ cells, only very few γ/δ TcR+ cells (maximum 5 cells/mm2) were seen 
intraepithelially or in the lamina propria in the gliadin or potassium iodine challenged sites. 
Similarly, the oral blister specimen from one patient (II, p.133) did not show any γ/δ TcR+ 
cells in contrast to marked amounts of α/β TcR+ cells. 
 
 
8.4 Oral findings in coeliac disease patients with associated Sjögren’s syndrome (IV) 
 
8.4.1 Oral mucosal findings 
 
The patients with CD+SS (90%) and with SS (95%) more often (p<0.001) gave a history of 
mouth dryness than the patients with CD (40%, IV: Table 2). The frequency of macroscopic 
mucosal lesions was high in the SS (80%), lower in the CD+SS (65%) and lowest in the CD 
(40%, p=0.043) group (Table 6). Six patients with CD+SS, six with SS and one with CD had 
mucosal ulcers. The mucosal and dental findings in the three patients with DH in each study 
group were in the line with those observed in the patients with CD. 
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Table 6.  Oral mucosal findings in the patients with coeliac disease (CD) and associated 
Sjögren’s syndrome (SS), and in the case controls of the patients with either coeliac disease or 
Sjögren’s syndrome alone. 
 CD+SS group  
(n=20)
CD group  
(n=20)
SS group 
(n=20)
Mucosal
Abnormalities
13 (65%) 8 (40%) 16 (80%) 
Patchy redness 8 3 13 
Ulcers 6 1 6 
Lichenoid/ 
Hyperplastic changes 
3 4 7 
Leukoplakia 1 2 5 
The mean number of affected mucosal locations was 1.7 (range 1-4) in the CD+SS, 2.0 (range 
1-3) in the CD and 3.1 (range 1-5) in the SS group (table 5.).  
44
Figure 1. Distribution of oral mucosal lesions in the patients with coeliac disease associated 
with Sjögren’s syndrome and in the patients with coeliac disease and Sjögren’s syndrome 
alone.
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8.4.2 Dental findings
Twelve patients with CD+SS had teeth compared to 17 with CD and 16 with SS (p=0.25, 
Table 2). The median number of teeth was 6 in the CD+SS, 24 in the CD (p=0.072) and 22 in 
the SS group. The DMF index was similar in the CD+SS (28) and SS (27) groups, but 
significantly lower (22, p=0.005) in the CD group. The frequency of coeliac-type enamel 
defects was 89% in the CD+SS and 88% in the CD group compared to 25% in the SS group 
(p<0.001, Table 2).   
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8.4.3 Radiological findings 
 
The mean PMI index was about the same in the CD+SS (0.37), CD (0.38) and SS (0.40) 
group. Similarly, no differences were found in the mean mandibular alveolar bone resorption 
index in the CD+SS (2.82), CD (2.83) and SS (2.94) groups. 
 
8.4.4 Salivary flow rates and salivary gland inflammatory focus score  
 
The stimulated salivary flow rate was within the normal range (>0.7ml/min) in the patients 
with CD+SS and CD, but significantly low in the patients with SS (0.3ml/min, p<0.001). The 
lacrimal excretion value in the Shirmer test was normal (8.2 mm/5min) in the patients with 
CD, but decreased in patients with CD+SS (3.7 mm/5min) and SS (1.5 mm/5min) (p=0.003). 
The salivary gland inflammatory focus score was highest (median 5.5) in the patients with SS, 
lower in the CD+SS (3.7) and lowest (p=0.002) in the CD (2.1) group (table 2). 
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9.  DISCUSSION 
 
9.1 Salivary IgA antigliadin antibodies in the patients with dermatitis herpetiformis. (I) 
 
Earlier studies had shown that patients with CD can have salivary IgA AGA antibodies in the 
saliva (Al-Bayaty et al 1989, Hakeem et al 1992). The salivary IgA AGA levels in the patients 
with DH, however, were only about 10% of the corresponding levels in the serum and similar 
to those of healthy controls. In addition, the salivary IgA AGA levels did not decrease during 
GFD treatment unlike the serum IgA AGA levels. These results are in agreement with the 
findings of the studies in children (Rujner et al 1996) and adults with CD (Kelly et al 1991, 
O’Mahony et al 1991, Lähteenoja et al 1999). As salivary IgA is mostly of secretory type, 
separate control mechanisms for serum and salivary IgA AGA responses could explain the 
present results. In contrast to IgA antibodies, salivary IgG is mostly derived from gingival 
crevicular fluid. In agreement with this, we found IgG AGA only in only a third of the present 
patients with DH. Similarly Lähteenoja et al (1999) found salivary IgG AGA in only 20% of 
patients with CD.  
 
 
9.2 Inflammatory changes in oral mucosa of the patients with dermatis herpetiformis 
(II-III) 
 
Increased density of γ/δ TcR+ lymphocytes in the jejunal mucosa is a constant marker of 
gluten-sensitive enteropathy in CD and DH (Holm et al 1992, Savilahti et al 1997). Therefore, 
we examined whether increased numbers of γ/δ TcR+ lymphocytes might also occur in the 
oral mucosa of patients with DH (II). We found, however, only a few γ/δ TcR+ cells in the 
buccal epithelium or lamina propria, but rather high densities of α/β TcR+ cells. These 
findings were confirmed in a similar study performed by Lähteenoja et al (2000) in the 
patients with CD. In contrast to DH and CD, increased amounts of γ/δ TcR+ lymphocytes 
were found in the lesions of recurrent aphthous stomatitis (Natah et al 2000). 
 
We also challenged buccal mucosa in the patients with DH by potassium iodine and gliadin to 
study the macroscopic and microscopic inflammation and especially whether gliadin causes 
an influx of γ/δ TcR+ cells into the mucosa (III). The gliadin challenge caused a marked 
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influx of CD4+ lymphocytes in the epithelium and increase of α/β TcR+ lymphocytes in the 
lamina propria, whereas the numbers of CD8+ lymphocytes and γ/δ TcR+ cells remained 
unaltered. These findings are in general similar to those observed in the patients with CD by 
Lähteenoja et al (2000a, 2000b). In contrast to the findings in the oral mucosa and small 
intestine, a gluten challenge did not cause any influx of T lymphocytes into the DH skin and 
the few T lymphocytes observed seem not to be gluten-specific (Baker et al 1995, Garioch et 
al 1995). Oral mucosal challenge with potassium iodine did not cause macroscopic lesions 
like in the skin. 
 
 
9.3 Oral findings in coeliac disease patients with associated Sjögren’s syndrome (IV) 
 
More than a half of the patients with CD have been reported to present with various oral 
mucosal abnormalities (Lähteenoja et al 1998), and coeliac-type dental enamel defects are 
typical features both for CD and DH (Aine 1996, Aquirre et al 1997). Patients with SS 
frequently have dental caries due to decreased salivary flow (Najera et al 1997, Konttinen et 
al 1997, Pertovaara 2001). CD and SS are frequently associated (Collin et al 1994) and 
patients suffering concomitantly from both disorders could be at even higher risk for mucosal 
and dental abnormalities. In agreement with this, we found that eight of the 20 patients with 
CD+SS had lost their teeth, and the median number of teeth in the CD+SS group was only 6 
compared to 24 in the CD and 22 in the SS group. This difference did not reach statistical 
significance (p=0.072). However, in the patients with CD+SS the DMF index was 
significantly higher than in those with CD and as high as in the patients with SS. This 
suggests that the increased caries index is in part linked to impaired salivary gland function 
typical of SS (Pedersen et al 1999). The stimulated salivary flow rate was, however 
significantly less impaired in the patients with CD+SS than in those with SS only. It is 
therefore, possible that the coeliac-type dental enamel defects, the prevalence of which was as 
high as 89% in the CD+SS group, could have an additive effect on the caries risk. 
 
In agreement with Lähteenoja et al (1998) we found macroscopic mucosal changes in as many 
as 40% of the present patients with CD. The prevalence was even higher in the patients with 
CD+SS (65%) and highest (80%) in those with SS. This suggests that the low salivary flow 
rate and concomitant dryness in the mouth in SS affect mucosal health more than the mucosal 
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inflammation typical for CD. In line with the lower frequency of mucosal changes and higher 
salivary flow rates, the patients with CD+SS had a lower salivary gland inflammatory focus 
score than the patients with SS only, though this was not significant. The reason could be that 
the patients with CD+SS had adhered to a GFD for several years. Diagnosis of CD at an early 
age has been shown to prevent the later development of associated autoimmune disorders 
(Ventura et al 1999) and the same seems true in adult patients adhered to a GFD for many 
years (Collin et al 1997). 
 
Interestingly, the median focus score of the 20 patients with CD was 2.1 and the interquartile 
range values of 1.0 and 3.1. This implies that many of the patients with CD could have a 
subclinical autoimmune focal sialoadenitis characteristic of SS. This finding also suggests that 
the overlap between CD and SS may be more extensive than is apparent at first sight. It is also 
a matter of discussion whether SS in the patients with CD should be classified as secondary or 
primary SS. 
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10. CONCLUSIONS AND FUTURE ASPECTS 
 
DH, a life-long blistering skin disease with pathognomonic IgA deposits in the skin and oral 
mucosa, is at present considered to be a cutaneous phenotype of CD (Reunala 2001, Fry 2002, 
Oxentenko&Murray 2003, Karpati 2004). CD is a common autoimmune disorder in which the 
small-intestinal mucosa are damaged by wheat gluten and related cereal peptides by a HLA 
DQ2 restricted, CD4+ T cell driven inflammation (Mäki&Collin 1997, Shan et al 2002, 
Mowat 2003). The formation of IgA class autoantibodies to tissue type transglutaminase 
(TG2) and their deposition in the intestinal mucosa seems to be of importance in the 
pathomechanism of small intestinal lesion (Dieterich et al 2003, Korponay-Szabo et al 2004, 
Reif&Lerner 2004).  
A recent serological screening study by Mäki et al (2003) in Finland showed that the 
prevalence of CD may be as high as 1/100. Many CD cases remain subclinical due to which 
there has been an obvious need to develop sensitive and specific serological screening tests 
(Mäki&Collin 1997). At first, screening was performed by measuring IgA and IgG class 
AGA with ELISA (Unsworth et al 1981, Vainio et al 1983). When IgA AGA was found also 
in saliva, it was suggested that salivary IgA AGA measurements could be used as a non-
invasive screening test for gluten-sensitive enteropathy in CD (Al-Bayaty et al 1989, Hakeem 
et al 1992). The first aim of the present study (1) was to examine whether IgA AGA also 
occurs  in the saliva of  patients with DH and, if so, whether measurement of salivary IgA 
AGA could be used to monitor the progress of GFD treatment as well as measurement of 
serum IgA AGA (Savilahti et al 1983, Vainio et al 1985). The salivary IgA AGA levels in the 
patients with DH, however, were only about 10% of the corresponding levels in the serum 
and similar to those of healthy controls (I). Though IgA class EmA is more specific than 
AGA in serological screening of gluten-sensitive enteropathy (Reunala et al 1987), 
measurement of IgA EmA from saliva in patients with CD also gave unsatisfactory results 
(Rujner et al 1995, Lähteenoja et al 1999). The same was true when IgA TGA was measured 
with ELISA (Baldas et al 2004). However, another recent study using radioimmunoassay 
found IgA TGA in the saliva of almost every patient with CD, but in none of the controls 
(Bonamico et al 2004). One reason for the high sensitivity and specificity seems to be the use 
of genetically produced TG2 antigen and a sensitive fluid-phase RIA method. In the same 
study it was found that the saliva volume to be used in the TGA RIA had to be 15 times that 
  
 
50 
of the serum volume (Bonamico et al 2004), a finding which is in line with the present IgA 
AGA ELISA results from saliva and serum. Due to the much lower IgA antibody 
concentration in saliva compared to serum and the need for radioactive reagents, it seems that 
saliva TGA RIA cannot at present replace serum TGA ELISA in the routine screening of 
gluten-sensitive enteropathy in CD or DH.  
The second aim of the present study (2) was to examine whether gamma/delta T cell receptor 
bearing lymphocytes occur in the oral mucosa of  patients with DH in similar high numbers 
as in the jejunal mucosa. Previously it has been shown that an increase of the number of γ/δ 
TcR+ lymphocytes in the jejunal mucosa is a constant marker for untreated patients with CD 
and DH (Halstensen et al 1989, Holm et al 1992, Savilahti et al 1992). γ/δ TcR+ lymphocytes 
are found particularly in the epithelium, whereas α/β TcR+ lymphocytes occur both in the 
epithelium and lamina propria. In the present study in the patients with DH (II) we found only 
single γ/δ TcR+ cells in the buccal epithelium and lamina propria, but rather high densities of 
α/β TcR+ cells. These findings were confirmed in a similar study performed by Lähteenoja et 
al (2000) in the patients with CD. 
The third aim of the present study (3) was to investigate the inflammatory reaction caused by 
potassium iodine and gliadin application on the oral mucosa in patients with DH. Gliadin 
challenge caused an influx of CD4+ lymphocytes in the epithelium and a significant increase 
of α/β TcR+ lymphocytes in the lamina propria, whereas the numbers of CD8+ lymphocytes 
and γ/δ TcR+ cells remained unaltered (III). These findings are in general similar to those 
observed in patients with CD by Lähteenoja et al (2000a) although their patients were GFD 
treated and the present patients untreated. Lähteenoja et al (2000b) also injected a synthetic 
gliadin-like peptide submucosally and found an influx of α/β TcR+ cells and increased 
expression of IL-2 receptor, an activation marker, on the T lymphocytes. Knowledge about 
the homing receptors expressed by orally invading T cells would also be of interest. To be 
active in the gut, gliadin has to be digested by trypsin and pepsin, and then modified by tissue 
transglutaminase in order to obtain the immunodominant, 33-dimer peptide, which then 
causes T lymphocyte activation and cytokine secretion (Sollid et al 1997, Shan et al 2002, 
Dieterich et al 2003). Whether this peptide causes a similar influx of CD4 + and α/β TcR+ 
cells in the oral buccal mucosa as that observed in the present study or that by Lähteenoja et al 
(2000b) needs to be examined. 
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The fourth aim of the present study (4) was to examine whether patients suffering 
concomitantly from CD and SS have a higher frequency of oral mucosal, dental and salivary 
abnormalities than  patients with either disorder alone. Previously patients with CD and DH 
have been reported to present with recurrent aphthous ulcers and coeliac-type dental enamel 
defects (Fergusson et al 1976, Aine 1996). In agreement with a previous study by Lähteenoja 
et al (1998), 40% of the present patients with CD had macroscopic mucosal changes (IV). 
Like the patients with Lähteenoja et al (1998), the present patients had been on a GFD several 
years suggesting that the observed mucosal changes were not related to malabsorption-related 
deficiency of iron, vitamins or trace elements (Barry et al 1974, Ferguson et al 1976). A 
prospective study on the occurrence of macroscopic mucosal changes at diagnosis and after 
adherence to a GFD with serial determinations of calcium, iron and various vitamins would 
confirm or exclude the possible malabsorption-related background of the observed mucosal 
changes.  
CD and DH are also associated with other autoimmune diseases such as type I diabetes and 
SS (Collin et al 2002, Hervonen et al 2004). SS, which occurs in about 3% of the patients 
with CD, also has an autoimmune background and is characterized by inflammation of the 
salivary glands (Syrjänen 1982). Decreased salivary flow causes dryness of the mouth, which 
increases risk for caries in SS (Konttinen et al 1997). Whether patients with CD+SS might 
have a higher prevalence of oral mucosal and dental lesions than those with either disease 
alone has not been previously studied. In the present study (IV) eight (40%) of the 20 patients 
with CD+SS had completely lost their teeth and the mean number of teeth was only 6 in the 
CD+SS group compared to 24 in the CD and 22 in the SS group. The DMF index was high 
(28 and 27, respectively) in the CD+SS and SS groups, but significantly lower in the CD 
group. The high DMF in the CD+SS group could be linked to the impaired salivary function 
typical of SS and also to coeliac-type dental enamel defects seen in 89% of these patients. 
These coeliac-type enamel defects can lead to the diagnosis of otherwise asymptomatic 
patients (Aine 1996). The diagnosis and treatment of both CD and SS as early as possible is a 
general goal and a further prospective study is needed to show whether active treatment of 
both these diseases and careful follow-up would prevent loss of teeth and improve oral health.  
Interestingly, the median inflammatory focus score in the minor salivary glands of the 20 
patients with CD was 2.1, whereas the normal score is < 1. This implies that many of the 
patients could have subclinical autoimmune focal sialoadenitis characteristic for SS. This 
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finding should be studied in a larger patient series consisting of both untreated and GFD 
treated patients with CD and DH. If confirmed, the increased salivary gland inflammation in 
patients with CD and those with CD+SS could be caused by an autoimmune inflammation 
specific for CD. Recently, Korponay-Szabo et al (2004) showed IgA TGA deposition in 
addition to jejunum also to extraintestinal tissues such as liver and lymph nodes. This is true 
also for DH skin (Sardy et al 2002). TG2 is a ubiquitous enzyme, which is present in many 
tissues including epithelial cells of salivary glands (Lee et al 1996, Lorand&Graham2002). A 
further study is, therefore, needed to examine whether the salivary glands could also be a 
target for IgA TGA deposition and further harmful inflammation in CD and DH. 
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